Tocagen to Present at Upcoming Jefferies 2019 Healthcare Conference

SAN DIEGO, May 30, 2019 /PRNewswire/ -- Tocagen Inc. TOCA, a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall, chief executive officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, at 4:00 p.m. ET in New York City.

The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen's website. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 30 days following the presentation.

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial (Toca 5) for recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration awarded Tocagen an orphan drug grant for the Toca 5 trial and has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG. The European Medicines Agency has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of high grade glioma.

Tocagen Media Contact:
Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com 

Tocagen Investor Contact:
Pete Rahmer
Endurance Advisors
(415) 515-9763
prahmer@enduranceadvisors.com  

SOURCE Tocagen Inc.